ES2391613T3 - Un procedimiento para purificar el factor de coagulación VIII - Google Patents

Un procedimiento para purificar el factor de coagulación VIII Download PDF

Info

Publication number
ES2391613T3
ES2391613T3 ES09769279T ES09769279T ES2391613T3 ES 2391613 T3 ES2391613 T3 ES 2391613T3 ES 09769279 T ES09769279 T ES 09769279T ES 09769279 T ES09769279 T ES 09769279T ES 2391613 T3 ES2391613 T3 ES 2391613T3
Authority
ES
Spain
Prior art keywords
fviii
resin
buffer
stage
multimodal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09769279T
Other languages
English (en)
Spanish (es)
Inventor
Carin Borgvall
Ulrika Ericsson
Gustav Gilljam
Mats Jernberg
Stefan Winge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octapharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40076764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2391613(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma AG filed Critical Octapharma AG
Application granted granted Critical
Publication of ES2391613T3 publication Critical patent/ES2391613T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
ES09769279T 2008-06-24 2009-06-24 Un procedimiento para purificar el factor de coagulación VIII Active ES2391613T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12940208P 2008-06-24 2008-06-24
EP08158893 2008-06-24
US129402P 2008-06-24
EP08158893 2008-06-24
PCT/EP2009/057883 WO2009156430A1 (en) 2008-06-24 2009-06-24 A process of purifying coagulation factor viii

Publications (1)

Publication Number Publication Date
ES2391613T3 true ES2391613T3 (es) 2012-11-28

Family

ID=40076764

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12179389.7T Active ES2538706T3 (es) 2008-06-24 2009-06-24 Procedimiento de purificación del factor de coagulación VIII
ES09769279T Active ES2391613T3 (es) 2008-06-24 2009-06-24 Un procedimiento para purificar el factor de coagulación VIII

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12179389.7T Active ES2538706T3 (es) 2008-06-24 2009-06-24 Procedimiento de purificación del factor de coagulación VIII

Country Status (19)

Country Link
US (1) US8329871B2 (da)
EP (2) EP2300497B1 (da)
JP (1) JP5619738B2 (da)
KR (3) KR20160104740A (da)
CN (1) CN102066417B (da)
AU (1) AU2009264282B2 (da)
BR (1) BRPI0914695B1 (da)
CA (1) CA2728047C (da)
DK (2) DK2300497T3 (da)
ES (2) ES2538706T3 (da)
IL (3) IL209758A (da)
MX (1) MX2010013908A (da)
PL (1) PL2300497T3 (da)
PT (1) PT2300497E (da)
RU (2) RU2698392C2 (da)
SI (1) SI2300497T1 (da)
UA (1) UA100901C2 (da)
WO (1) WO2009156430A1 (da)
ZA (1) ZA201009162B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0814220B8 (pt) 2007-07-11 2021-05-25 Novo Nordisk As purificação de fator viii usando uma resina multimodal ou de modo misto
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
BRPI0917656A2 (pt) 2008-08-21 2017-07-11 Octapharma Ag Fatores viii e ix humanos produzidos de forma recombinante
CN107050437A (zh) * 2008-09-03 2017-08-18 奥克塔法马股份有限公司 重组制备的因子viii的新型保护组合物
US20110166332A1 (en) * 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
RU2015149979A (ru) * 2010-03-30 2019-01-15 Октафарма Аг Способ очистки белка фактора роста
AU2011234521B2 (en) * 2010-03-30 2015-04-23 Octapharma Ag A process for purifying Vitamin K dependent proteins such as coagulation factor IX
ES2545893T3 (es) 2010-04-20 2015-09-16 Octapharma Ag Nuevo agente estabilizante para proteínas farmacéuticas
WO2012049285A1 (en) 2010-10-14 2012-04-19 Octapharma Ag A method for the quantitative glycosylation analysis of proteins
EP2635600B1 (en) 2010-11-05 2017-06-21 F. Hoffmann-La Roche AG Optimized method for antibody capturing by mixed mode chromatography
RU2600886C2 (ru) * 2011-05-13 2016-10-27 Октафарма Аг Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii
CN103688177B (zh) 2011-06-17 2017-07-04 学校法人东日本学园 狼疮抗凝物检测用血液凝固时间的测定方法
WO2013062841A1 (en) * 2011-10-26 2013-05-02 Bio-Rad Laboratories, Inc. Removal of virucidal agents in mixed mode chromatography
EP2911759A1 (en) * 2012-10-24 2015-09-02 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
CN103880947B (zh) * 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
RU2662929C2 (ru) * 2013-03-08 2018-07-31 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
WO2014201400A2 (en) * 2013-06-13 2014-12-18 Biogen Idec Ma Inc. Anti-factor viii antibodies or uses thereof
SG11201508835YA (en) 2013-07-12 2015-11-27 Merck Patent Gmbh Removal of fragments from a sample containing a target protein using activated carbon
EP3875106A1 (en) * 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) * 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
CN106414491B (zh) * 2014-01-20 2021-06-18 奥克塔法马股份有限公司 一种制备FVIII:C/FVIII:Ag比例提高的因子VIII的方法
US20160347787A1 (en) * 2014-02-04 2016-12-01 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN104861060A (zh) * 2014-02-21 2015-08-26 神州细胞工程有限公司 一种纯化凝血因子viii的方法
SG11201609815QA (en) 2014-05-29 2016-12-29 Agency Science Tech & Res Protein Extraction Methods
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
SG11201912962RA (en) * 2017-06-23 2020-01-30 Baxalta Inc Purification of factor viii subspecies
CN107226859B (zh) * 2017-08-10 2020-11-24 博雅生物制药集团股份有限公司 一种人凝血因子ⅷ的制备方法
WO2019045149A1 (en) * 2017-08-31 2019-03-07 Green Cross Corporation PROCESS FOR PURIFYING SULFATASE PROTEIN
EP3843869A1 (en) 2018-08-31 2021-07-07 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
US20230092867A1 (en) * 2020-01-20 2023-03-23 WuXi Biologics Ireland Limited A novel wash buffer solution for affinity chromatography

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5316680A (en) * 1992-10-21 1994-05-31 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for using same
JPH08506710A (ja) 1993-06-11 1996-07-16 ノーザン・テレコム・リミテッド ユーザ制御呼管理サービス方法および装置
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
AUPR638801A0 (en) * 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
AU2005216847B2 (en) 2004-02-27 2010-04-01 Cytiva Bioprocess R&D Ab A process for the purification of antibodies
PL1765866T3 (pl) * 2004-06-07 2014-06-30 Therapure Biopharma Inc Wydzielanie białek osocza lub surowicy
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
FR2887883B1 (fr) * 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
ZA200900229B (en) 2006-07-14 2010-04-28 Genentech Inc Refolding of recombinant proteins
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
EP2108046B9 (en) * 2007-02-01 2014-03-26 Baxter International Inc. Fviii-independent fix-mutant proteins for hemophilia a treatment
DK2167117T3 (da) * 2007-06-13 2012-11-19 Csl Behring Gmbh Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser
BRPI0814220B8 (pt) * 2007-07-11 2021-05-25 Novo Nordisk As purificação de fator viii usando uma resina multimodal ou de modo misto
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
ES2538706T3 (es) 2015-06-23
IL209758A (en) 2014-02-27
DK2537862T3 (da) 2015-06-15
RU2698392C2 (ru) 2019-08-26
MX2010013908A (es) 2011-01-21
DK2300497T3 (da) 2012-10-29
RU2015141849A (ru) 2018-12-28
RU2015141849A3 (da) 2018-12-28
CA2728047C (en) 2019-07-30
CN102066417B (zh) 2015-11-25
US20110160435A1 (en) 2011-06-30
KR20110038634A (ko) 2011-04-14
KR20160104740A (ko) 2016-09-05
CN102066417A (zh) 2011-05-18
BRPI0914695B1 (pt) 2022-04-19
US8329871B2 (en) 2012-12-11
KR101804136B1 (ko) 2017-12-04
UA100901C2 (ru) 2013-02-11
JP5619738B2 (ja) 2014-11-05
PT2300497E (pt) 2012-10-30
EP2537862B1 (en) 2015-03-18
EP2537862A1 (en) 2012-12-26
CA2728047A1 (en) 2009-12-30
PL2300497T3 (pl) 2013-02-28
SI2300497T1 (sl) 2013-02-28
EP2300497A1 (en) 2011-03-30
IL209758A0 (en) 2011-02-28
IL229583B (en) 2018-03-29
KR20170102065A (ko) 2017-09-06
RU2567811C2 (ru) 2015-11-10
WO2009156430A1 (en) 2009-12-30
ZA201009162B (en) 2011-10-26
KR101700722B1 (ko) 2017-01-31
AU2009264282A1 (en) 2009-12-30
RU2011102437A (ru) 2012-07-27
IL229583A0 (en) 2014-01-30
BRPI0914695A2 (pt) 2015-10-20
JP2011525523A (ja) 2011-09-22
EP2300497B1 (en) 2012-08-08
AU2009264282B2 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
ES2391613T3 (es) Un procedimiento para purificar el factor de coagulación VIII
JP5323072B2 (ja) 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
ES2740825T3 (es) Un procedimiento de purificación de proteínas dependientes de vitamina K
ES2670827T3 (es) Proceso para la purificación del factor estimulador de colonias de granulocitos, G-CSF
JP5883849B2 (ja) 陰イオン交換樹脂を用いる二価カチオン結合タンパク質の精製方法
ES2224245T3 (es) Purificacion del complejo factor viii mediante cromatografia de inmunoafinidad.
AU2014230101B2 (en) Purification method for vitamin K dependent proteins by anion exchange chromatography